SA Novavax vaccine trial shows efficacy against B.1.351 Covid-19 variant

6th May 2021

By: Sane Dhlamini

Creamer Media Senior Contributing Editor and Researcher

     

Font size: - +

Results from the University of the Witwatersrand Novavax coronavirus (Covid-19) vaccine trial show 51% efficacy against the B.1.351 variant in a South African study with HIV negative participants.

A group in the trial, which included people who are HIV positive, showed 43% efficacy.

Novavax is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes Covid-19 disease. 

Professor of Vaccinology, co-author of the study, and the director of the Wits Vaccines & Infectious Diseases Analytics Research Unit Shabir Madhi led the Novavax Covid-19 vaccine trial in South Africa.

Publication of initial primary analysis showed cross-protection by the Novavax Covid-19 vaccine against the B.1.351 variant, making it the first published study to show protection against mild Covid-19 caused by the B.1.351 variant.

An updated analysis of the study indicated 100% protection against severe Covid-19 due to the B.1.351 variant.

“An efficacy of 50% is sufficient to meet the World Health Organization criteria for regulatory approval of the vaccine,” Madhi said.

The New England Journal of Medicine also published findings of the Phase 2b clinical trial conducted in South Africa on Wednesday.

Founder of Intercell USA, Inc. and president of research and development at Novavax Gregory M. Glenn says this data publication reinforces the encouraging safety profile and cross-protective effect across variants seen in studies of the vaccine to-date.

 

Edited by Sashnee Moodley
Senior Deputy Editor Polity and Multimedia

Comments

The content you are trying to access is only available to subscribers.

If you are already a subscriber, you can Login Here.

If you are not a subscriber, you can subscribe now, by selecting one of the below options.

For more information or assistance, please contact us at subscriptions@creamermedia.co.za.

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?

MAGAZINE & ONLINE

SUBSCRIBE

RESEARCH CHANNEL AFRICA

SUBSCRIBE

CORPORATE PACKAGES

CLICK FOR A QUOTATION